Shalby

INR
139.75
1 (0.72%)
BSENSE

Mar 20

BSE+NSE Vol: 83.97 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

83.97 k (-29.78%) Volume

Shareholding (Dec 2025)

FII

4.47%

Held by 35 FIIs

DII

0.19%

Held by 1 DIIs

Promoter

74.33%

Who are in the management team of Shalby?

06-Jun-2025

As of March 2023, the management team of Shalby includes Vikram Shah (Chairman & Managing Director), Sushobhan Dasgupta (Vice Chairman), and several independent directors: Shyamal S Joshi, Umesh Menon, Ashok Bhatia, Tej Malhotra, Sujana Shah, and Vijay Kishanlal Kedia, along with Tushar Shah (Company Secretary & Compliance Officer).

As of March 2023, the management team of Shalby includes the following individuals:<BR><BR>1. Vikram Shah - Chairman & Managing Director<BR>2. Shyamal S Joshi - Independent Director<BR>3. Umesh Menon - Independent Director<BR>4. Ashok Bhatia - Independent Director<BR>5. Tej Malhotra - Independent Director<BR>6. Sujana Shah - Independent Director<BR>7. Tushar Shah - Company Secretary & Compliance Officer<BR>8. Sushobhan Dasgupta - Vice Chairman<BR>9. Vijay Kishanlal Kedia - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, along with key compliance and governance roles.

View full answer

When is the next results date for Shalby?

06-Jun-2025

No Upcoming Board Meetings

Has Shalby declared dividend?

06-Jun-2025

Yes, Shalby Ltd. has declared a 12% dividend, amounting to ₹1.2 per share, with an ex-date of September 19, 2024. Despite recent negative returns in the short term, long-term performance shows positive trends, particularly over the last five years.

Shalby Ltd. has declared a 12% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.66%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Shalby experienced a price return of -24.69%, with no dividend return, resulting in a total return of -24.69%.<BR><BR>Over the past year, the price return was -29.77%, with a dividend return of 0.43%, leading to a total return of -29.34%.<BR><BR>In the 2-year period, the price return was 28.62%, with a dividend return of 1.50%, resulting in a total return of 30.12%.<BR><BR>For the 3-year period, Shalby had a price return of 57.96%, a dividend return of 3.50%, culminating in a total return of 61.46%.<BR><BR>In the last 4 years, the price return was 6.68%, with a dividend return of 2.54%, leading to a total return of 9.22%.<BR><BR>Finally, over the 5-year period, Shalby achieved a price return of 167.0%, a dividend return of 7.00%, resulting in a total return of 174.0%.<BR><BR>Overall, while Shalby has declared a dividend, the recent total returns indicate significant volatility, particularly in the short term, with negative returns over the last year and six months. However, the longer-term returns show a more positive trend, especially over the 5-year period.

View full answer

Who are the peers of the Shalby?

03-Jun-2025

Shalby's peers include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, GPT Healthcare, KMC Speciality, Asarfi Hospital, and Chandan Healthcare. In terms of performance, Shalby has the lowest 1-year return at -28.92%, while Asarfi Hospital leads with a 110.53% return.

Peers: The peers of Shalby are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, GPT Healthcare, KMC Speciality, Asarfi Hospital, and Chandan Healthca.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, GPT Healthcare, and Chandan Healthca, while Good management risk is found at Apollo Hospitals, Narayana Hrudaya, Global Health, and Asarfi Hospital, and Average management risk is present at Fortis Health., Shalby, KMC Speciality, and the rest. For Growth, Excellent growth is seen at Max Healthcare and Chandan Healthca, Good growth at Apollo Hospitals, Narayana Hrudaya, and Fortis Health., while Below Average growth is noted at Shalby, GPT Healthcare, KMC Speciality, and the rest. In terms of Capital Structure, Excellent capital structure is held by Max Healthcare, Global Health, GPT Healthcare, KMC Speciality, and Chandan Healthca, while Average capital structure is found at Apollo Hospitals, and Good capital structure is observed at Fortis Health., Shalby, and Asarfi Hospital.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Asarfi Hospital at 110.53%, while Shalby has the lowest 1-year return at -28.92%. Shalby's return is significantly lower than all peers. Additionally, the peers with negative six-month returns include Shalby, GPT Healthcare, KMC Speciality, and Apollo Hospitals.

View full answer

What does Shalby do?

17-Jul-2025

Shalby Ltd. is a small-cap hospital company based in India, originally incorporated in 2004 and publicly listed since 2006. As of March 2025, it reported net sales of ₹2,649 Cr and a net loss of ₹110 Cr.

Overview:<BR>Shalby Ltd. operates in the hospital industry and is categorized as a small-cap company.<BR><BR>History:<BR>Shalby Ltd. was originally incorporated as 'Shalby Hospital Private Limited' in 2004. It transitioned to a public limited company in 2006, changing its name to 'Shalby Hospital Public Limited', then to 'Shalby Hospitals Limited', and finally to 'Shalby Limited' in 2008. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2,649 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: -110 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 2,096 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 345.00<BR>- Industry P/E: 59<BR>- Dividend Yield: 0.62%<BR>- Debt Equity: 0.35<BR>- Return on Equity: 0.63%<BR>- Price to Book: 2.10<BR><BR>Contact Details:<BR>- Address: Opp Karnawati Club, Sarkhej Gandhinagar Highway Ahmedabad Gujarat : 380015<BR>- Tel: 91-79-40203000<BR>- Email: companysecretary@shalby.in<BR>- Website: http://www.shalby.org

View full answer

Who are the top shareholders of the Shalby?

17-Jul-2025

The top shareholder of Shalby is the Shah Family Trust, led by Dr. Vikram Shah, with a 34.73% stake. Other notable shareholders include 38 foreign institutional investors with 5.2% and First Water Fund, the largest public shareholder, at 1.77%.

The top shareholders of Shalby include the Shah Family Trust, represented by Dr. Vikram Shah, who holds the largest stake at 34.73%. The company is primarily owned by its promoters, with no pledged promoter holdings. Additionally, there are 38 foreign institutional investors (FIIs) who collectively hold 5.2% of the shares. The highest public shareholder is First Water Fund, with a holding of 1.77%. Individual investors account for 11.2% of the total shareholding.

View full answer

How big is Shalby?

24-Jul-2025

As of 24th July, Shalby Ltd. has a market capitalization of 2,237.00 Cr, with recent net sales of 1,086.95 Cr and a net profit of 6.22 Cr. Shareholder's funds are 1,000.37 Cr and total assets amount to 1,607.53 Cr as of March 2024.

As of 24th July, <BR><BR>Shalby Ltd. has a market capitalization of 2,237.00 Cr, categorizing it as a Small Cap company. <BR><BR>For the latest four quarters, Shalby reported Net Sales of 1,086.95 Cr and a Net Profit of 6.22 Cr. <BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 1,000.37 Cr and Total Assets of 1,607.53 Cr.

View full answer

Is Shalby overvalued or undervalued?

09-Oct-2025

As of October 8, 2025, Shalby is considered very attractive and undervalued, with a PE ratio of -2742.37, a price-to-book value of 2.76, and strong long-term returns of 89.9% and 190.67% over three and five years, respectively, despite recent underperformance compared to peers like Apollo Hospitals and Max Healthcare.

As of 8 October 2025, the valuation grade for Shalby has moved from attractive to very attractive. The company is currently considered undervalued, particularly given its extreme PE ratio of -2742.37 and a price-to-book value of 2.76. Other notable ratios include an EV to EBITDA of 23.96 and a ROCE of 4.99%. <BR><BR>In comparison to its peers, Shalby stands out with a significantly lower PE ratio than Apollo Hospitals, which has a PE of 70.05, and Max Healthcare, which is at 92.31. Despite the negative sentiment reflected in the recent stock performance, where Shalby has underperformed the Sensex over the past week, its long-term returns over three and five years show a robust growth of 89.9% and 190.67%, respectively, reinforcing its undervaluation narrative.

View full answer

How has been the historical performance of Shalby?

01-Dec-2025

Shalby's historical performance shows strong revenue growth, with net sales increasing to 1,086.96 Cr by Mar'25, but rising expenditures led to a decline in operating profit and profit after tax, which fell to 1.92 Cr. Additionally, cash flow from operating activities turned negative in Mar'25, indicating potential liquidity issues.

Answer:<BR>The historical performance of Shalby shows significant growth in net sales and operating income over the years, with net sales increasing from 430.90 Cr in Mar'21 to 1,086.96 Cr in Mar'25. Total operating income followed a similar trend, reaching 1,086.96 Cr in Mar'25, up from 804.92 Cr in Mar'23. However, total expenditure also rose, climbing from 344.48 Cr in Mar'21 to 954.35 Cr in Mar'25, which impacted the operating profit, which decreased from 177.04 Cr in Mar'24 to 132.61 Cr in Mar'25. Profit before tax saw a decline from 128.19 Cr in Mar'24 to 55.73 Cr in Mar'25, leading to a profit after tax of only 1.92 Cr in Mar'25 compared to 83.50 Cr in Mar'24. The earnings per share dropped significantly from 7.83 in Mar'24 to 0.58 in Mar'25. On the balance sheet, total assets increased from 1,193.54 Cr in Mar'22 to 1,703.65 Cr in Mar'25, while total liabilities also rose from 1,193.54 Cr to 1,703.65 Cr in the same period. Cash flow from operating activities turned negative in Mar'25 at -4.00 Cr, contrasting with positive cash flows in previous years.<BR><BR>Breakdown:<BR>Shalby's financial performance has shown a robust increase in net sales, which rose from 430.90 Cr in Mar'21 to 1,086.96 Cr in Mar'25, indicating strong revenue growth. Total operating income mirrored this growth, reaching 1,086.96 Cr in Mar'25. However, total expenditure surged to 954.35 Cr in Mar'25, leading to a decline in operating profit from 177.04 Cr in Mar'24 to 132.61 Cr in Mar'25. This decline was further reflected in profit before tax, which fell from 128.19 Cr in Mar'24 to 55.73 Cr in Mar'25, resulting in a profit after tax of just 1.92 Cr in Mar'25. The earnings per share also saw a drastic drop from 7.83 in Mar'24 to 0.58 in Mar'25. On the balance sheet, total assets increased significantly to 1,703.65 Cr in Mar'25, while total liabilities rose correspondingly, indicating a growing debt load. Cash flow from operating activities turned negative in Mar'25, contrasting with positive cash flows in prior years, highlighting potential liquidity challenges.

View full answer

Is Shalby technically bullish or bearish?

02-Dec-2025

As of December 1, 2025, the market trend has shifted to mildly bearish, supported by bearish MACD readings, Bollinger Bands, and Dow Theory, despite some daily moving averages indicating mild bullishness.

As of 1 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by weekly and monthly MACD readings indicating bearish momentum, along with Bollinger Bands and KST both signaling bearish conditions. The Dow Theory also supports a mildly bearish outlook on both weekly and monthly time frames. Although daily moving averages show a mildly bullish signal, the overall technical indicators suggest a bearish sentiment prevailing in the market.

View full answer

Are Shalby Ltd. latest results good or bad?

12-Feb-2026

Shalby Ltd.'s latest Q3 FY26 results are concerning, showing a 78.90% decline in net profit and a 4.66% drop in revenue, marking two consecutive quarters of revenue decline. The company's performance is significantly below industry standards, indicating serious operational challenges and poor financial health.

Shalby Ltd.'s latest results for Q3 FY26 indicate a concerning performance. The company reported a net profit of ₹1.77 crore, which represents a dramatic decline of 78.90% quarter-on-quarter. Revenue also decreased by 4.66% to ₹272.13 crore, marking the second consecutive quarter of revenue decline. <BR><BR>The operating margin, excluding other income, fell significantly to 11.12% from 14.58% in the previous quarter, reflecting rising cost pressures and operational inefficiencies. Additionally, the profit before tax was just ₹9.23 crore, down from ₹19.07 crore in Q2 FY26, and an unusually high tax rate of 86.13% severely impacted net profitability.<BR><BR>In the context of the broader hospital sector, which has been experiencing robust growth, Shalby's underperformance stands out. The stock has also significantly lagged behind its peers, with a return of negative 17.25% over the past year compared to the hospital sector's positive 25.33% return.<BR><BR>Overall, the results reflect serious operational challenges and a deterioration in financial health, suggesting that the latest performance is indeed bad for Shalby Ltd.

View full answer

Should I buy, sell or hold Shalby Ltd.?

13-Feb-2026

Why is Shalby Ltd. falling/rising?

17-Mar-2026

As of 16-Mar, Shalby Ltd. is facing a stock price decline to Rs. 140.45, down 2.4%, with a new 52-week low of Rs. 137. The stock is underperforming its sector and major moving averages, indicating a bearish trend, while investor participation has significantly decreased.

As of 16-Mar, Shalby Ltd. is experiencing a decline in its stock price, currently at Rs. 140.45, which reflects a decrease of Rs. 3.45 or 2.4%. The stock has hit a new 52-week low of Rs. 137 today, indicating significant downward pressure. It has underperformed its sector by 0.86% and has been on a consecutive fall for the last two days, with a total decline of 4.91% during this period.<BR><BR>The stock opened with a gap down of 4.79% today and reached an intraday low of Rs. 137. Additionally, Shalby Ltd. is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically suggests a bearish trend. There has also been a notable drop in investor participation, with delivery volume falling by 63.85% compared to the 5-day average.<BR><BR>Despite some positive factors such as a strong ability to service debt and healthy long-term growth in net sales and operating profit, the stock's performance has been poor over the past year, generating a return of -31.84% and a significant profit decline of 76.2%. Furthermore, the company has been underperforming against benchmarks like the BSE500 over various time frames, which may contribute to investor hesitance. The lack of domestic mutual fund investment, holding only 0% of the company, could also indicate a lack of confidence in the stock's current valuation or business prospects.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Flat results in Dec 25

  • PBT LESS OI(Q) At Rs 2.00 cr has Fallen at -71.14%
  • ROCE(HY) Lowest at 6.10%
  • DEBT-EQUITY RATIO(HY) Highest at 0.53 times
2

Despite the size of the company, domestic mutual funds hold only 0% of the company

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Hospital

stock-summary
Market cap

INR 1,529 Cr (Small Cap)

stock-summary
P/E

187.00

stock-summary
Industry P/E

55

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.43

stock-summary
Return on Equity

0.45%

stock-summary
Price to Book

1.50

Revenue and Profits:
Net Sales:
272 Cr
(Quarterly Results - Dec 2025)
Net Profit:
2 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-29.9%
0%
-29.9%
6 Months
-41.94%
0%
-41.94%
1 Year
-31.26%
0%
-31.26%
2 Years
-40.21%
0.49%
-39.72%
3 Years
13.62%
1.71%
15.33%
4 Years
12.84%
2.57%
15.41%
5 Years
40.1%
3.85%
43.95%

Latest dividend: 1.2 per share ex-dividend date: Sep-19-2024

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

Announcements stock-summary

Disclosure Under Reg. 30 Of SEBI (LODR) Regulations 2015 - Major Development - Inauguration Of Oncology Department Along With Advanced Radiotherapy Facilities At Shalby Hospital Surat

09-Mar-2026 | Source : BSE

Shalby Limited has inaugurated its oncology department along with advanced Radiotherapy facilities at Shalby Multi-specialty Hospital Surat.

NABH Accreditation To PK Healthcare Pvt Ltd. (Shalby International Hospitals) - Subsidiary Company

03-Mar-2026 | Source : BSE

NABH Accreditation to PK Healthcare Pvt. Ltd. (Shalby Internatioal Hospitals) - Subsidiary Company

Credit Of Equity Shares By Subsidiary Company On Rights Issue Basis To The Company

28-Feb-2026 | Source : BSE

Credit of equity shares by subsidiary company on Rights Issue basis to the Company

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Shalby Ltd. has declared 12% dividend, ex-date: 19 Sep 24

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
23.17%
EBIT Growth (5y)
25.38%
EBIT to Interest (avg)
8.36
Debt to EBITDA (avg)
1.94
Net Debt to Equity (avg)
0.43
Sales to Capital Employed (avg)
0.68
Tax Ratio
91.97%
Dividend Payout Ratio
15.33%
Pledged Shares
0
Institutional Holding
4.66%
ROCE (avg)
8.10%
ROE (avg)
5.51%

Valuation key factors

Factor
Value
P/E Ratio
187
Industry P/E
55
Price to Book Value
1.51
EV to EBIT
29.13
EV to EBITDA
14.43
EV to Capital Employed
1.35
EV to Sales
1.73
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
5.00%
ROE (Latest)
0.45%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 2 Schemes (0.0%)

FIIs

Held by 35 FIIs (4.47%)

Promoter with highest holding

Shah Family Trust Throuh Dr. Vikram Shah, Trustee (34.79%)

Highest Public shareholder

First Water Fund (1.28%)

Individual Investors Holdings

11.72%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -1.27% vs 27.58% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 197.79% vs -109.49% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "272.13",
          "val2": "275.63",
          "chgp": "-1.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "30.26",
          "val2": "33.91",
          "chgp": "-10.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "10.64",
          "val2": "10.66",
          "chgp": "-0.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.77",
          "val2": "-1.81",
          "chgp": "197.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "11.12%",
          "val2": "12.30%",
          "chgp": "-1.18%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 6.48% vs 15.41% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -9.13% vs -60.65% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "581.86",
          "val2": "546.43",
          "chgp": "6.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "83.15",
          "val2": "77.86",
          "chgp": "6.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "19.02",
          "val2": "17.39",
          "chgp": "9.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "17.31",
          "val2": "19.05",
          "chgp": "-9.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "14.29%",
          "val2": "14.25%",
          "chgp": "0.04%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 3.88% vs 19.22% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 10.67% vs -74.45% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "853.99",
          "val2": "822.06",
          "chgp": "3.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "113.41",
          "val2": "111.77",
          "chgp": "1.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "29.66",
          "val2": "28.05",
          "chgp": "5.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "19.08",
          "val2": "17.24",
          "chgp": "10.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "13.28%",
          "val2": "13.60%",
          "chgp": "-0.32%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 16.41% vs 16.01% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -92.60% vs 24.19% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,086.96",
          "val2": "933.75",
          "chgp": "16.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "132.61",
          "val2": "177.04",
          "chgp": "-25.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "38.71",
          "val2": "16.03",
          "chgp": "141.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6.22",
          "val2": "84.08",
          "chgp": "-92.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "12.20%",
          "val2": "18.96%",
          "chgp": "-6.76%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
272.13
275.63
-1.27%
Operating Profit (PBDIT) excl Other Income
30.26
33.91
-10.76%
Interest
10.64
10.66
-0.19%
Exceptional Items
0.00
0.00
Consolidate Net Profit
1.77
-1.81
197.79%
Operating Profit Margin (Excl OI)
11.12%
12.30%
-1.18%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is -1.27% vs 27.58% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 197.79% vs -109.49% in Dec 2024

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
581.86
546.43
6.48%
Operating Profit (PBDIT) excl Other Income
83.15
77.86
6.79%
Interest
19.02
17.39
9.37%
Exceptional Items
0.00
0.00
Consolidate Net Profit
17.31
19.05
-9.13%
Operating Profit Margin (Excl OI)
14.29%
14.25%
0.04%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 6.48% vs 15.41% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is -9.13% vs -60.65% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
853.99
822.06
3.88%
Operating Profit (PBDIT) excl Other Income
113.41
111.77
1.47%
Interest
29.66
28.05
5.74%
Exceptional Items
0.00
0.00
Consolidate Net Profit
19.08
17.24
10.67%
Operating Profit Margin (Excl OI)
13.28%
13.60%
-0.32%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 3.88% vs 19.22% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2025 is 10.67% vs -74.45% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
1,086.96
933.75
16.41%
Operating Profit (PBDIT) excl Other Income
132.61
177.04
-25.10%
Interest
38.71
16.03
141.48%
Exceptional Items
0.00
0.00
Consolidate Net Profit
6.22
84.08
-92.60%
Operating Profit Margin (Excl OI)
12.20%
18.96%
-6.76%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 16.41% vs 16.01% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -92.60% vs 24.19% in Mar 2024

stock-summaryCompany CV
About Shalby Ltd. stock-summary
stock-summary
Shalby Ltd.
Small Cap
Hospital
Shalby Ltd was originally incorporated as a Private Limited Company with the name 'Shalby Hospital Private Limited' on August 30, 2004. Subsequently, the Company was converted to a Public Limited Company and the name was changed to 'Shalby Hospital Public Limited' on May 15, 2006. Further, the name of the Company was changed to Shalby Hospitals Limited on July 26, 2006 and then, again changed to Shalby Limited on February 13, 2008.
Company Coordinates stock-summary
Company Details
Opp Karnawati Club, Sarkhej Gandhinagar Highway Ahmedabad Gujarat : 380015
stock-summary
Tel: 91-79-40203000
stock-summary
companysecretary@shalby.in
Registrar Details
Karvy Computershare Pvt Ltd., Karvy Selenium, Tower-B Plot No 31 & 32, Survey No 116/22, 115/24, 115/25, Financial District, Nanakramguda, Serilingampally, Mandal Ranga Reddy Dist, Hyderabad